PLA2G7: A Protein with Multiple Functions and Potential as A Drug Target

Target Name: PLA2G7

NCBI ID: G7941

PLA2G7

PLA2G7: A Protein with Multiple Functions and Potential as A Drug Target

PLA2G7 (Pro-lylated advanced G protein-coupled receptor 7) is a protein that is expressed in various tissues and cells in the body. It is a member of the G protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a key role in cellular signaling. PLA2G7 is characterized by its unique structure, which consists of a long extracellular domain, a short transmembrane region, and a short intracellular tail.

One of the key functions of PLA2G7 is its role in cell signaling. It is involved in a wide range of physiological processes in the body, including cell adhesion, migration, and signaling pathways that regulate cell behavior. PLA2G7 has been shown to play a key role in the regulation of neurotransmitter release from neurons, which is critical for a wide range of brain function.

PLA2G7 is also of interest as a potential drug target. Due to its involvement in multiple cellular signaling pathways, PLA2G7 has been identified as a potential target for a variety of drugs, including neurotransmitter antagonists, kinase inhibitors, and GPCR antagonists. Several PLA2G7-targeted drugs are currently in development, including small molecule inhibitors and monoclonal antibodies.

In addition to its potential as a drug target, PLA2G7 is also of interest as a biomarker. Its expression is regulated by a variety of factors, including cytokines, chemokines, and signaling pathways that are involved in cell signaling. This makes PLA2G7 an attractive candidate for use as a biomarker for a wide range of diseases, including neurodegenerative disorders, pain, and cancer.

PLA2G7 is also of interest as a potential therapeutic target for a variety of diseases. Its involvement in multiple cellular signaling pathways makes it a potential target for a wide range of drugs, including neurotransmitter antagonists, kinase inhibitors, and GPCR antagonists. Several PLA2G7-targeted drugs are currently in development, including small molecule inhibitors and monoclonal antibodies. These drugs have the potential to treat a wide range of diseases, including neurodegenerative disorders, pain, and cancer.

In conclusion, PLA2G7 is a protein that is of interest as a drug target and biomarker. Its unique structure and multiple functions make it a potential target for a wide range of drugs, including neurotransmitter antagonists, kinase inhibitors, and GPCR antagonists. Its potential as a biomarker for a variety of diseases, as well as its potential as a therapeutic target for a wide range of conditions, makes PLA2G7 a promising molecule for further study and development.

Protein Name: Phospholipase A2 Group VII

Functions: Lipoprotein-associated calcium-independent phospholipase A2 involved in phospholipid catabolism during inflammatory and oxidative stress response (PubMed:7700381, PubMed:8624782, PubMed:2040620, PubMed:16371369, PubMed:17090529, PubMed:10066756). At the lipid-aqueous interface, hydrolyzes the ester bond of fatty acyl group attached at sn-2 position of phospholipids (phospholipase A2 activity) (PubMed:2040620, PubMed:10504265). Specifically targets phospholipids with a short-chain fatty acyl group at sn-2 position (PubMed:2040620). Can hydrolyze phospholipids with long fatty acyl chains, only if they carry oxidized functional groups (PubMed:2040620, PubMed:8624782). Hydrolyzes and inactivates platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine), a potent pro-inflammatory signaling lipid that acts through PTAFR on various innate immune cells (PubMed:10504265, PubMed:10066756, PubMed:7592717, PubMed:11590221, PubMed:7700381, PubMed:18434304, PubMed:16371369, PubMed:8675689, PubMed:8624782). Hydrolyzes oxidatively truncated phospholipids carrying an aldehyde group at omega position, preventing their accumulation in low-density lipoprotein (LDL) particles and uncontrolled pro-inflammatory effects (PubMed:2040620, PubMed:7700381). As part of high-density lipoprotein (HDL) particles, can hydrolyze phospholipids having long-chain fatty acyl hydroperoxides at sn-2 position and protect against potential accumulation of these oxylipins in the vascular wall (PubMed:17090529). Catalyzes the release from membrane phospholipids of F2-isoprostanes, lipid biomarkers of cellular oxidative damage (PubMed:16371369)

The "PLA2G7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLA2G7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets